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Through a computational approach, five new compounds 
with potent and selective Rac inhibitory activity were 
identified. In particular, compound 4 was shown to selectively 
inhibit Rac activity in a concentration-dependent manner by 10 
affecting the GEF-dependent GDP-GTP exchange. This 
compound was more potent than the original inhibitors 
previously identified. 
Introduction 
In the last decade, the small GTPase protein Rac has gained 15 
increasing attention for its role on cardiovascular diseases. 
Transgenic mice expressing a constitutively activated Rac1 
mutant in the myocardium developed either a lethal cardiac 
dilated phenotype or a transient cardiac hypertrophy that resolved 
with age.1 In line with this evidence, cardiomyocyte knock-out 20 
specific mice for Rac1 are resistant to cardiac hypertrophy 
induced by angiotensin infusion.2 The role of Rac on cardiac 
function has been associated with its regulatory function on the 
NADPH activity and thus generation of reactive oxygen species.2 
Moreover, endothelial Rac1 haploinsufficient mice showed 25 
decreased expression and activity of eNOS which correlated with 
the decrease in endothelium-dependent vasorelaxation, and 
caused mild hypertension.3 This evidence suggests a protective 
role of Rac on endothelial cells and more in general on vascular 
diseases. Various agonists and extracellular matrix appears to be 30 
required for a proper Rac1-mediated modulation of endothelial 
barrier property, through the involvement of reactive oxygen 
species and actin cytoskeleton.4-6 However, Rac directly regulates 
many other cellular events associated with the development of 
atherosclerotic plaque, including smooth muscle cell (SMC) 35 
migration7 and proliferation,8 and leukocyte-endothelial cell 
interaction.9 Thus, the final outcome of the role of Rac on 
cardiovascular diseases is still controversial. Nevertheless, 
pathway-based genome-wide association analysis of coronary 
heart disease (CHD) has identified Rac1 as one of the 40 
biologically important gene in CHD, thus indicating that Rac 
represents a possible new pharmacological target for 
cardiovascular diseases.10 
 In 2004 it was described a new approach for the identification 
of selective Rac inhibitors that specifically interfere with the 45 
protein-protein interaction between Rac and the guanine 
nucleotide exchange factor (GEF).11 More recently, we took 
advantage from this evidence to identify new Rac inhibitors by a 
pharmacophore virtual screening approach followed by molecular 
docking calculations.12 These new inhibitors were shown to be 50 
selective on Rac, without affecting RhoA and Cdc42 activities, 
and to interfere with the binding between the GEF Tiam1 and its 
substrate Rac, thus blocking the exchange between GDP and GTP 
and Rac activation.12 In particular, the two -
(sulfamoylaryl)arylamide derivatives 1 and 2 (Fig. 1) resulted the 55 
most potent. In the present study, to explore the potentiality of 
these hits, a selection of commercially available -
(sulfamoylaryl)arylamides variously substituted at the two 
regions shown in Fig. 2, was identified by virtual screening and 
tested for their Rac inhibitory potency. 60 
 
 
Fig. 1  Previously reported hit compounds 1 and 2. 
Results and Discussion 
Virtual screening. Starting from the hit compounds 1 and 2 (Fig. 65 
1),12 a similarity search was performed directly on the ZINC DB 
website.13 The clustering and search algorithms implemented in 
ZINC are based on a search engine provided by ChemAxon were 
both the query and molecules in the DB are represented by 
fingerprints, and the similarity degree is expressed as a Tanimoto 70 
coefficient (TC). 
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Fig. 2  Selected regions of interest for chemical modification. 
 
 All the molecules with a TC value of ≥ 0.85 with respect to 
either compounds 1 (53 derivatives) and 2 (117 derivatives) were 5 
selected for molecular docking evaluation. As the receptor, the 
previously derived 3D model12 was used and a consensus docking 
strategy using two different software, MOE14 and Autodock4 
(AD4),15 and a total of three scoring functions (London dG and 
Affinity, implemented in MOE, and the default AD4 scoring 10 
function) was adopted as it proved to be a rather successful 
screening strategy.12 Energies obtained by MOE and AD4 virtual 
screenings were compared and only those compounds for which 
the computed docking energies resulted above defined thresholds 
(affinity < -4.5, London dG < -7.0, AD4 binding energy < -6.5 15 
kcal/mol) were selected. Within this selection, a total of 57 
commercially available -(sulfamoylaryl)arylamides with 
differences in regions 1 and 2 (Fig. 2) were selected and acquired 
for biochemical testing. 
 20 
Identification of new selective Rac inhibitors by in vitro and cell-
based assays. The pharmacological inhibition of the identified 
compounds on Rac activity was studied in cultured human SMCs 
by determining the amount of Rac-GTP by G-LISA assay.12  
 To induce Rac activation, human SMCs were starved for 48 h 25 
in DMEM containing 0.4 % of FCS and then stimulated for 2 min 
with 20 ng/mL platelet derived growth factor (PDGF)-BB. The 
effect of tested compounds was assessed by a 4 h pre-incubation 
of human SMC before stimulation. In a first series of G-LISA 
assays, a final non-toxic concentration of the 57 selected 30 
compounds was utilized, (between 10 and 200 µM) as determined 
by MTT cytotoxicity assay (data not shown). Among the 57 
tested compounds, 23 efficiently reduced the intracellular content 
of Rac-GTP from a minimum of 24.8 % to a maximum of 63.7 % 
(Table S1, ESI). Importantly, five compounds were shown to be 35 
more effective than the reference compound 1 and fifteen were 
more effective than compound 2, indicating a potential 
improvement of the pharmacological inhibition of Rac by the 
newly identified chemical entities. 
 A second series of analysis was performed at 25 µM 40 
concentration in order to select the most potent compounds. 
Compounds 3, 4, 5, 11 and 21 showed the most potent inhibitory 
action on Rac protein and consistently reduced, by more than 
50%, the intracellular amount of Rac-GTP (Table 1 and Table S2, 
ESI). A dose dependent effect on Rac activity showed that 45 
compounds 5 and 4 have the lowest IC50 values, 4.4 µM and 8.7 
µM, respectively (Table 2, Fig. S1, ESI). 
 
Table 1 Effect of selected compounds on Rac1 GTP levels. 50 
  
 
 
 
cmpd R1 R2 R3 R4 R5 R6 X % inhibition at 25 µM 
21 H CH3 H CH3 CH3 H -CH2- 68.3±6.3 *** 
3 H CH3 H H H H -CH2- 67.4±1.5 *** 
11 H CH3 H H CH3 H -CH2- 65.3±9.0 *** 
4 H H H H H H -CH2- 61.1±3.0 *** 
5 H H H CH3 CH3 H -CH2- 59.3±1.2*** 
6 H H CH3 H H H -CH2- 51.9±3.1** 
10 H H CH3 CH3 CH3 H -CH2- 46.5±17.7
 NS 
20 H H CH3 CH3 H CH3 -CH2- 45.5±24.2 * 
14 H H H CH3 CH3 H -CH2-CH2- 40.8±21.4* 
16 H H H H CH3 H -CH2-CH2- 26.1±3.8 *** 
24 H H CH3 H CH3 CH3 -CH2- 21.9±0.2
 NS 
15 H H H H H H -CH2-CH2- NE 
NE: Not effective; NS: Not significant 
*p<0.05; **p<0.01; ***p<0.001 Student’s T-test. 
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Fig. 3  Determination of the selectivity of the new Rac 
inhibitors. Cells were seeded at a density of 2 x 105/35 mm petri 
dish and incubated with DMEM supplemented with 10% FCS; 5 
24h later the medium was changed to one containing 0.4% FCS, 
and the cultures were incubated for 48 h. At this time, the 
compounds were added to the cultured media at the final 
concentration of 25 µM and after 4 h Rac and RhoA activation 
was induced by PDGF-BB (10 ng/ml) for 2 min. Total protein 10 
extracts and G-LISA assays were then performed. 
 
Table 2  Effect of selected compounds on Rac1-GTP levels and 
Cell Adhesion with calculated IC50 values. 
 15 
Cmpd Rac1-GTP levels IC50 (µM) Cell adhesion IC50 (µM) 
3 16.4±2.1 5.3±0.9 
4 8.7±2.4 8.7±2.7 
5 4.4±3.1 21.3±1.8 
11 19.2±2.8 27.9±2.4 
21 29.1±5.1 24.2±4.2 
 
 In order to determine the selectivity of action of the tested 
compounds on Rac, the G-LISA assay specific for RhoA was 
performed. As shown in Fig. 3, compounds 3, 4, 5, and 21 
strongly reduced the intracellular levels of Rac-GTP without 20 
significantly affecting the activity of RhoA, while compound 11 
appears to be less Rac-selective. It should be noted that 
compound 3 has been tested as either a racemate or single 
enantiomers, but analogue results were obtained probably due to 
the scarce steric hindrance of the methyl group at position 3 of 25 
the piperidine ring (data not shown). 
 Time-dependent effect of compound 4 clearly demonstrated 
that that its inhibitory effect on Rac is selective and very rapid 
with a significant reduction of Rac-GTP after 1 h of incubation 
(Fig. S2, ESI).  30 
 To further investigate the basic molecular mechanism of Rac 
inhibition, we examined the effect of compound 4 on the 
exchange activity of Tiam 1 and TrioN, Rac-specific GEFs 16, 17 
and Vav2, a GEF active on Rac1, RhoA, and Cdc42.18 The 
treatment with compound 4 strongly reduced the Rac1-GTP 35 
levels induced by SMCs expressing either Tiam1, TrioN, or 
Vav2. These results indicate that compound 4 interferes with the 
GEF-mediated Rac activation (Fig. S3, ESI). 
 To delineate the anti-Rac activity of the selected compounds in 
cultured cells, the effect on Rac1-dependent cell adhesion was 40 
evaluated. Rac activity has been previously shown to be required 
for cell adhesion,19 and its downregulation by siRNA directed to 
Rac1 strongly reduced the capability of cells to adhere to the petri 
dish (Fig. S4, ESI). The effect of the six selected new Rac 
inhibitors on a cell adhesion was then determined. SMCs were 45 
incubated for 4 h with increasing concentrations of compounds 
(10-50 µM), harvested by trypsinization, and then cell adhesion 
was determined. All the compounds were capable to significantly 
affect cell adhesion in a concentration dependent manner (Table 
2, Fig. S5, ESI). In particular, compounds 4, 11 and 21 showed 50 
very similar IC50 values on the cell adhesion and the inhibitory 
action on Rac, demonstrating the effective inhibition of a Rac-
mediated cellular event by these compounds (Table 2). Finally, 
compound 4 was shown to inhibit lamellipodia formation in 
human SMCs induced by PDGF-BB (Fig. S6, ESI), a cellular 55 
response strikingly related to Rac1 activity.20 
 
Structure activity relationships and binding mode analysis. 
Concerning Structure Activity Relationships, the 3,5-substituted 
pyrazole moiety generally wield a more potent activity compared 60 
to the phenyl moiety, especially if combined with an 2-
hydroxyphenyl substituent. 
 Taking as a reference the compound 4 as the lesser substituted 
and one of the more potent molecules, we can see that the 
modification of the sulfon-piperidinamide moiety with the sulfon-65 
azepanamide analog causes a total loss of activity, like in 
compound 15, that can be partially restored by adding one or two 
methyl substituent on the phenol ring like in compound 16 and 
compound 14. The rationale behind the phenol substitution is not 
trivial, in fact, compound 23 is inactive. By taking again 70 
compound 4 as a reference, the methylation of the piperidine ring 
substantially change the molecule activity. Indeed, modification 
at position 4 lead to a significant decrease in activity, as observed 
for compound 6, compound 10, compound 20 and compound 24. 
The substitution of the pyrazole moiety with its benzocondensate 75 
(the previously reported compound 2)12 also leads to lower 
efficacy. The methylation at position 3 of the piperidine ring 
cause instead an increment in activity, as observed for compound 
1, and, in this case, the methylation of the phenol ring leads to the 
most effective molecule compound 21. 80 
 A binding mode prediction for the most active compounds 3, 
4, 5, 11 and 21 has been obtained through the QM Polarized 
Ligand Docking workflow, present in the Schrodinger 2011 
software suite,21 followed by force field minimization of each 
pose, maintaining the receptor fixed, performed with the MOE 85 
software. 
 The best poses, selected after visual inspection, are generally 
recurrent for the same chemical family of compound (Fig. 4). The 
post-docking energy minimization using the MMFF94x force 
field reduces the diversity of the poses but only in few cases the 90 
RMSD between the minimized and non-minimized pose exceeds 
2 Å (the 8% of the total poses), indicating that the QM polarized 
docking protocol is already efficient on his own. 
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Fig. 4  Proposed binding mode for compounds 
21 (carbon colored in grey, green, orange, ochra and purple, 
respectively). Compound NSC23766 (carbon colored in 5 
magenta), whose binding mode has been resolved by X
crystallography, is also reported as a reference. 
 
Table 3.  Most relevant binding contacts for compounds 
and 21 10 
 ligand-receptor interactions
cmpd residue type of interaction
3 Lys5 CH/π (3-aryl···H
 Ala59 H-bond (SO2···HN)
4 Trp56 CH/π (3-aryl C6-
 Ala59 H-bond (SO2···HN)
5 Trp56 CH/π (3-aryl C6-
 Ala59 H-bond (SO2···HN)
11 Ala59 H-bond (SO2···HN)
 Leu70 H-bond (pyrazole 1H
21 Trp56 CH/π (3-aryl C6-
 Ala59 H-bond (SO2···HN)
 
 Basing on the obtained poses, we can assume that the 
sulfonamide Rac inhibitors, herein reported, present an analogue 
binding mode (Fig. 4), which can be compared to the one 
described for the reference compound NSC23766.15 
reported in Table 3 and graphically depicted in Fig. S7, ESI, t
important interaction with TRP56 is maintained 
5 and 21 by the aryl group trough a CH/π bond, while 
group of compound 3 interacts with the Lys5 
itself interacts with the indole moiety of Trp5620 
interaction, peculiar for the class of compounds herein reported, 
is established within the SO2 moiety and Ala59
compound 11, an H-bond can also be observed between the 
pyrazole NH and the Leu70 carbonyl group.
interactions between the piperidine group and the pocket formed 25 
by Val36, Ala59, Tyr64 and Leu67 (although not reported in 
Table 3) could also be observed for all compound 
inspection of the complexes. 
Conclusions 
Starting from previously identified hits,12 by using a virtual 30 
screening approach we identified a series of 3
aminoylsulfonylphenyl-1H-pyrazole-5-carboxamides 
This journal is © The Royal Society of Chemistry [year]
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as potent 
and selective Rac inhibitors. 
 In particular, compounds 4 and 
activity with IC50 values lower than the previously reported 
compounds 1 and 2 (8.7 µM and 4.4
and 24.1 µM, respectively).12 The effect of the new compounds 55 
was then studied on cell adhesion, a cell
linked to Rac activity. These set of experiments were considered 
more indicative of the effect of the new compounds on Rac 
functionality than the determination 
Rac-GTP levels. The results of this analysis confirmed that all the 60 
compounds inhibited the cell adhesion with IC
those observed by G-LISA assay. This observation demonstrated 
a direct relationship between the levels of Rac
on cell adhesion. In particular, compound 
potent compound and inhibited the cell adhesion with an IC65 
8.7 µM equal to that observed by G
completely inhibited lamellipodia formation in response to 
PDGF, a Rac1-dependent cellular response, further confirming its 
inhibitory action on Rac functionality. 
 Other small molecules with Rac1 inhibitory activity has been 
described after the firstly discovered compound NSC23766,
some differences in their mechanisms of action. Compounds 85 
and 2 appear to act, similarly to NSC23766, by interfering with 
the Rac1-Tiam1 interaction. The same effect was shown for 
NSC23766 which also interferes with the binding Rac1
while the effect on Vav2, another GEF capable to activates Rac, 
was not assessed.11 Compound 4 described in the present report, 90 
was shown to affect the Rac activity induced by three different 
GEFs, Tiam1, TrioN, or Vav2, and thus with a similar 
mechanism of action as demonstrated for compounds 
NSC23766. A more specific inhibitory action was then observed 
for the compound ITX3 which interferes with Trio without 95 
affecting the activation of Rac and RhoG by both Tiam1 and 
Vav2.23 Differently, compound EHop
described potent Rac inhibitor, affects Vav2
exchange of Rac and shows a ten-
and probably no effect on Trio.24 While Vav2 is a GEF active on 100 
Rac1, RhoA, and Cdc42, compound EHop
interfere only with Rac-Vav2 interaction, a sele
potentially responsible for the observed increased of RhoA 
activation in cancer cells for the higher availability of Vav2.
“Interestingly, compound 4 has shown a trend of induction of 105 
RhoA activity, although not statistically significant, suggesting a 
similar compensatory effect than that observed for compound 
EHop-016.” A third chemical entity, compound EHT 1864, has 
been discovered to selectively inhibit Rac without interfering 
with the binding between Rac an110 
mechanism of action has not yet been resolved, form the obtained 
data it has been suggested a possible allosteric mechanism 
determining a loss of bind with nucleotide.
 In conclusion, through a computational ap
a new class of Rac inhibitors that potently and selectively reduced 
the intracellular levels of Rac GTP and its activity, demonstrated 
by effects on the lamellipodia formation and cell adhesion. These 
effects appear to be related to the inhibition of GEF95 
GTP-GDP exchange on Rac, since compound 
activation induced by either Tiam1, TrioN or Vav2, implying a 
selective interference of Rac1-GEF interaction similar to that 
 
5 selectively inhibited Rac 
 µM compared to 12.2 µM 
-based assay directly 
of the intracellular levels of 
50 values similar to 
-GTP and its action 
4 was the second most 
50 of 
-LISA assay. Compound 4 
 
 with 
1 
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4 affected Rac 
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described for compound 1 and 2 and NSC23766. This compound 
appears to be suitable for investigating its effect on 
atherosclerotic plaque formation in in-vivo experimental models. 
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